Literature DB >> 18553225

Chemotherapy for gastric cancer in Japan.

Masahiko Nishiyama1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18553225     DOI： 10.1007/s10147-008-0790-2

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN： 1341-9625            Impact factor:   3.402


× No keyword cloud information.
  19 in total

1.  Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations.

Authors:  Hei-Cheul Jeung; Sun Young Rha; Hoon Kyo Kim; Ho Young Lim; Samyong Kim; Si Young Kim; Soo Jeong Gong; Chan Hee Park; Joong Bae Ahn; Sung Hoon Noh; Hyun Cheol Chung
Journal:  Oncologist       Date:  2007-05

2.  Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma.

Authors:  Jaffer A Ajani; Josephine Faust; Kazumasa Ikeda; James C Yao; Hiroshi Anbe; Kelli L Carr; Michele Houghton; Peter Urrea
Journal:  J Clin Oncol       Date:  2005-09-06       Impact factor: 44.544

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

4.  Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.

Authors:  Kazuhiro Yoshida; Motoki Ninomiya; Norihisa Takakura; Naoki Hirabayashi; Wataru Takiyama; Yuji Sato; Satoru Todo; Masanori Terashima; Mitsukazu Gotoh; Jyunnichi Sakamoto; Masahiko Nishiyama
Journal:  Clin Cancer Res       Date:  2006-06-01       Impact factor: 12.531

5.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

6.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

7.  Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002).

Authors:  Noriya Uedo; Hiroyuki Narahara; Ryu Ishihara; Hiroya Takiuchi; Masahiro Goto; Kazumasa Fujitani; Motohiro Hirao; Toshimasa Tsujinaka; Motohiro Imano; Hiroshi Furukawa; Hideaki Tsukuma; Tetsuo Taguchi
Journal:  Oncology       Date:  2008-03-12       Impact factor: 2.935

8.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

9.  Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

Authors:  Atsushi Ohtsu; Yasuhiro Shimada; Kuniaki Shirao; Narikazu Boku; Ichinosuke Hyodo; Hiroshi Saito; Noboru Yamamichi; Yoshinori Miyata; Nobumasa Ikeda; Seiichiro Yamamoto; Haruhiko Fukuda; Shigeaki Yoshida
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

10.  Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer.

Authors:  E Mochiki; T Ohno; Y Kamiyama; R Aihara; N Haga; H Ojima; J Nakamura; H Ohsawa; T Nakabayashi; K Takeuchi; T Asao; H Kuwano
Journal:  Br J Cancer       Date:  2006-11-28       Impact factor: 7.640
View more
  3 in total

1.  The prognostic significance of chemotherapy for stage IV gastric cancer patients: a single-institution experience.

Authors:  Toshiro Okuyama; Daisuke Korenaga; Kenichi Koushi; Shinji Itoh; Hirofumi Kawanaka; Yasuharu Ikeda; Kenji Takenaka
Journal:  Surg Today       Date:  2011-07-12       Impact factor: 2.549

Review 2.  Docetaxel: its role in current and future treatments for advanced gastric cancer.

Authors:  Masahiko Nishiyama; Satoru Wada
Journal:  Gastric Cancer       Date:  2009-11-05       Impact factor: 7.370

3.  Function of chloride intracellular channel 1 in gastric cancer cells.

Authors:  Peng-Fei Ma; Jun-Qiang Chen; Zhen Wang; Jin-Lu Liu; Bo-Pei Li
Journal:  World J Gastroenterol       Date:  2012-06-28       Impact factor: 5.742
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.